This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Plasmapheresis in myasthenia gravis

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Plasmapharesis is a therapeutic option in myasthenia gravis:

  • plasma exchange does no better than immunosuppression in reducing circulating levels of the anti-AChR antibody and in inducing clinical improvement
  • main role is in helping to relieve a myasthenic crisis, in preparing patients for a thymectomy and post-operatively, and in covering the increased weakness that may occur when corticosteroid treatment is begun (1)
  • plasma exchange is usually followed by 3-5 weeks of improved strength.
  • may be needed repeatedly in patients with chronic and severe weakness while immunosuppressive treatment becomes effective

IV immunoglobulin (IVIg) or plasmapheresis can be used in severe disease and exacerbations, but plasmapheresis is probably better for true myasthenic crises

  • plasmapheresis may produce a more rapid response, but IVIg is less expensive and may have fewer complications.


Related pages

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.


Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.